Tonix Pharmaceuticals (NASDAQ: TNXP) investors are having a bad week. Hot off the heels of a devastating interim analysis from one of its late-stage clinical trials that looks all but doomed to end in failure, the stock's price has fallen well below $1. Given that its other late-stage programs target notoriously difficult-to-treat conditions, including post-traumatic stress disorder (PTSD) and Alzheimer's disease, the entire company is looking quite frail.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting